CytoDyn (CYDY) Income from Continuing Operations (2010 - 2026)
CytoDyn (CYDY) posted Income from Continuing Operations of 4690000.0 for Q1 2026, up 79.25% on a QoQ basis from 22607000.0 in Q4 2025, and up 1.43% year-over-year from 4623916.29 in Q1 2025.
CytoDyn (CYDY) Income from Continuing Operations (2010 - 2026) Analysis & Trends
CytoDyn's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 4690000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 1.43% year-over-year to 4690000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 38793000.0 (down 447.46% YoY) and the FY2025 annual result came in at 3745000.0, up 107.51% from the prior year.
- Income from Continuing Operations was 4690000.0 for Q1 2026 at CytoDyn, up from 22607000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 19227000.0 in Q3 2024 and bottomed at 84121000.0 in Q2 2022.
- A 5-year average of 16714058.82 and a median of 11920000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 266.17% — and 2025, when it slumped 374.14%.
- CytoDyn's Income from Continuing Operations stood at 26495000.0 in 2022, then surged by 63.91% to 9563000.0 in 2023, then surged by 50.14% to 4768000.0 in 2024, then tumbled by 374.14% to 22607000.0 in 2025, then soared by 79.25% to 4690000.0 in 2026.
- Business Quant data shows CYDY's Income from Continuing Operations at 4690000.0 in Q1 2026, 22607000.0 in Q4 2025, and 5540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | CytoDyn | 248.66 Mn | 248.66 Mn | - | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.69 Mn |
| Nov 30, 2025 | -22.61 Mn |
| Aug 31, 2025 | -5.54 Mn |
| May 31, 2025 | -5.96 Mn |
| Feb 28, 2025 | -4.76 Mn |
| Nov 30, 2024 | -4.77 Mn |
| Aug 31, 2024 | 19.23 Mn |
| May 31, 2024 | -16.79 Mn |
| Feb 29, 2024 | -11.92 Mn |
| Nov 30, 2023 | -9.56 Mn |
| Aug 31, 2023 | -11.57 Mn |
| May 31, 2023 | -18.61 Mn |
| Feb 28, 2023 | -13.70 Mn |
| Nov 30, 2022 | -26.50 Mn |
| Aug 31, 2022 | -20.99 Mn |
| May 31, 2022 | -84.12 Mn |
| Feb 28, 2022 | -41.29 Mn |
| Nov 30, 2021 | -40.08 Mn |
| Aug 31, 2021 | -45.34 Mn |
| May 31, 2021 | -70.07 Mn |